Is Scancell the best penny stock for me to buy today?

The Scancell share price is on fire, jumping by 50% since July! But is this just the tip of the iceberg for this upcoming biotech penny stock?

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny Stock Scancell Holdings (LSE:SCLP), has seen its share price jump more than 50% in the last four months. The biotech group has been on a bit of a roll, hitting some solid milestones in its drug development pipeline while also bringing in new expertise to the management team.

So, it’s not surprising to see investors take an interest in this little enterprise. But the question is, at around 15p, is it among the best penny stocks to buy right now?

A year of progress

As a quick crash course, Scancell is an immunotherapy drug research business focused on various forms of cancer. Its primary development pipeline currently consists of four vaccines, two of which are in Phase 2 trials, and four antibodies.

Over the last few months, the board of directors has been getting some fresh talent. In July, Dr Florian Reinaud joined as a non-executive director. A few weeks later, Dr Nermeen Varawalla joined the group as chief medical officer. And shortly after that, Dr Phil L’Huillier was appointed as the new chief executive officer.

Each appointee has an impressive amount of experience within the healthcare industry, both from a medical and managerial perspective. And with L’Huillier having already served as CEO at another biotech group in Germany, steering the business to success, there’s reason for optimism, in my opinion.

Meanwhile, the latest clinical trial results continue to look promising. Its flagship SCIB1 drug, which targets unresectable melanoma, has delivered encouraging results from its ongoing Phase 2 trials so far. Its Modi-1 drug, which targets a variety of other cancers, is also showing good safety, with the expansion of cohorts on track.

In other words, the drugs are seemingly meeting expectations so far. And should these trends continue, Scancell could be getting primed to reap enormous future revenue.

Taking a step back

Seeing solid progress being made in the fight against cancer is terrific. But from an investment perspective, it’s impossible to ignore the risks associated with Scancell. Penny stocks are already high-risk opportunities. But this risk skyrockets when entering into the world of biotech.

Based on current timelines, SCIB1 isn’t expected to complete Phase 2 trials until 2026. And looking at industry averages, it could be as late as 2030 before Phase 3 trials are completed.

In the meantime, Scancell has no revenue stream, which makes it entirely dependent on external financing. Right now, there’s around £15m in cash on its balance sheet, helping keep the lights on. But sadly, that won’t be nearly enough to fund research and development over the next six+ years.

What does this mean for investors? Most likely, shareholders can expect a lot of equity dilution moving forward as Scancell looks to raise capital. We’ve already seen a 50% dilution over the last five years, with the number of shares outstanding rising from 476m in 2020 to 929m today.

In the long run, this may not matter. After all, if Scancell is successful, even after dilution, shareholders could reap enormous returns. However, clinical trials are notoriously difficult. And with the firm’s fate entirely dependent on external investors offering capital, all it takes is one bad result to send the share price plummeting.

That’s why, despite the explosive opportunity, this isn’t a penny stock I’m rushing to buy right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are we soon to see a skyrocketing stock market?

The stock market could be on the verge of surging next year as interest rates fall and innovation takes off,…

Read more »

Investing Articles

How I’d use £10 a day to build a lifetime of passive income

Zaven Boyrazian explains his three-step plan to help generate a passive income in 2024 by putting aside just £10 a…

Read more »

Stack of one pound coins falling over
Investing Articles

Unlocking a £111k yearly second income starting with a £20k ISA!

Taking advantage of a tax-free account to invest in stocks is a smart way to build towards a substantial future…

Read more »

Investing Articles

Warning! 2 FTSE 100 shares I think could collapse in 2025

The FTSE could be in for another strong year in 2025 as interest rates fall. But the outlook may be…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

2 cheap penny stocks for growth AND dividends!

Royston Wild thinks these penny stocks are great all-rounder options for his portfolio. At current prices, are they too cheap…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Best British value stocks to consider buying in November

We asked our freelance writers to reveal their top value shares, including a Share Advisor 'Fire' stock first recommended almost…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 reasons why I’ll avoid cheap Barclays shares in November!

Barclays shares look like a bona-fide bargain based on predicted earnings. But Royston Wild thinks the FTSE 100 bank remains…

Read more »

Investing Articles

2 FTSE 100 stocks I’d buy and hold to 2035

A lump sum investment in these FTSE 100 stocks could reap massive returns over the next decade and are worth…

Read more »